Psyence Biomedical Ltd

자세한 내용은 Psyence Biomedical Ltd 회사

Psyence Biomedical Ltd is a multi-asset, vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics. The Company is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. It is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer.

회사 정보

회사 코드PBM

회사 이름Psyence Biomedical Ltd

상장일Dec 10, 2021

설립일2023

CEODr. Neil Maresky

직원 수- -

유형Ordinary Share

회계 연도 종료Dec 10

주소121 Richmond Street West Penthouse

도시TORONTO

증권 거래소NASDAQ Capital Market Consolidated

국가Canada

우편 번호M5H 2K1

전화17744604171

웹사이트

회사 코드PBM

상장일Dec 10, 2021

설립일2023

회사 임원

이름

이름/직위

직위

주식 보유

변동

Dr. Jody Aufrichtig

Chairman of the Board, Strategic Business Development Officer

--

Dr. Neil Maresky

Chief Executive Officer, Director

--

Mr. Warwick Corden-Lloyd

Chief Financial Officer

--

Mr. Marc Balkin

Independent Director

--

Mr. Christopher (Chris) Bull

Independent Director

--

Dr. Seth Feuerstein

Independent Director

--

이름

이름/직위

직위

주식 보유

변동

Dr. Jody Aufrichtig

Chairman of the Board, Strategic Business Development Officer

--

Dr. Neil Maresky

Chief Executive Officer, Director

--

Mr. Warwick Corden-Lloyd

Chief Financial Officer

--

Mr. Marc Balkin

Independent Director

--

Mr. Christopher (Chris) Bull

Independent Director

--

Dr. Seth Feuerstein

Independent Director

--

수익 분석

데이터 없음

데이터 없음

사업별

지역별

데이터 없음

주주

업데이트 시간: Sat, May 17

주주 통계

유형

주주 통계

주주

비율

Sabby Management, LLC

5.52%

White Lion Capital LLC

2.15%

Citadel Advisors LLC

1.62%

Essential Planning, LLC

1.58%

Virtu Americas LLC

0.78%

Other

88.35%

주주 통계

주주

비율

Sabby Management, LLC

5.52%

White Lion Capital LLC

2.15%

Citadel Advisors LLC

1.62%

Essential Planning, LLC

1.58%

Virtu Americas LLC

0.78%

Other

88.35%

유형

주주

비율

Investment Advisor/Hedge Fund

5.52%

Investment Advisor

3.16%

Venture Capital

2.24%

Hedge Fund

1.90%

Research Firm

0.79%

Corporation

0.59%

Other

85.80%

기관 주식 보유

업데이트 시간: Tue, Mar 4

보고 기간

기관 수

보유 주식

비율

변동

2025Q1

44

195.77K

33.56%

+174.05K

2024Q4

82

948.20K

24.27%

+587.08K

2024Q3

88

169.92K

15.90%

-186.51K

2024Q2

92

159.62K

36.84%

-203.47K

2024Q1

96

157.41K

35.61%

-211.56K

2023Q4

88

18.95K

16.18%

-253.66K

2023Q3

87

16.58K

55.18%

-252.44K

2023Q2

86

17.96K

50.97%

-264.02K

2023Q1

85

19.55K

55.14%

-329.89K

2022Q4

82

277.86K

79.72%

-42.11K

주주 활동

이름

보유 주식

비율

변동

Chg %

날짜

White Lion Capital LLC

100.00K

2.21%

+100.00K

--

Dec 04, 2024

Citadel Advisors LLC

11.49K

0.25%

+9.23K

+409.08%

Dec 31, 2024

Essential Planning, LLC

73.28K

1.62%

+73.28K

--

Dec 31, 2024

Virtu Americas LLC

12.69K

0.28%

+12.69K

--

Dec 31, 2024

AdvisorShares Investments, LLC

26.92K

0.59%

+10.49K

+63.84%

Dec 31, 2024

UBS Financial Services, Inc.

12.71K

0.28%

+12.51K

+6.26K%

Dec 31, 2024

Launchpad Ignition Holdings LLC

15.92K

0.35%

+15.92K

--

Mar 31, 2024

Tabula Rasa Ltd

11.53K

0.25%

-5.80K

-33.47%

Mar 31, 2024

4.420USD